NASDAQ : LYCA
Lycia Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 26.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.52B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Lycia Therapeutics, Inc. (LYCA) reported revenue of 4.43M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 4.43M | 6.74M | 14.94M |
| Gross Profit | 12.93M | 6.74M | 14.94M |
| Selling, General & Admin | 6.23M | 6.11M | 6.40M |
| Research & Development | 40.51M | 40.51M | 41.07M |
| Operating Expenses | 46.74M | 46.62M | 47.47M |
| Operating Income | -33.81M | -39.88M | -32.53M |
| Interest Expense | -26.00K | -31.00K | -39.00K |
| Interest & Investment Income | 3.73M | 4.83M | 6.19M |
| Other Non Operating Income (Expenses) | -50.00K | -102.00K | -117.00K |
| EBT Excluding Unusual Items | -30.16M | -35.18M | -26.50M |
| Merger & Restructuring Charges | -121.00K | -1.53M | |
| Pretax Income | -30.28M | -36.71M | -26.50M |
| Income Tax Expense | -249.00K | -249.00K | 7.00K |
| Net Income | -30.03M | -36.46M | -26.50M |
| Net Income to Common | -30.03M | -36.46M | -26.50M |
| Shares Outstanding (Basic) | 14.36M | 14.10M | 13.40M |
| Shares Outstanding (Diluted) | 14.36M | 14.10M | 13.40M |
| EPS (Basic) | -2.09 | -2.59 | -1.98 |
| EPS (Diluted) | -2.09 | -2.59 | -1.98 |
| Free Cash Flow | -33.79M | -51.56M | -30.77M |
| Free Cash Flow Per Share | -2.35 | -3.66 | -2.30 |
| Gross Margin | 291.48% | 100.00% | 100.00% |
| Operating Margin | -762.32% | -591.57% | -217.82% |
| Profit Margin | -677.16% | -540.87% | -177.44% |
| Free Cash Flow Margin | -761.83% | -764.81% | -206.03% |
| EBITDA | -32.84M | -38.69M | -31.36M |
| EBITDA Margin | -209.94% | ||
| D&A For EBITDA | 974.00K | 1.19M | 1.18M |
| EBIT | -33.81M | -39.88M | -32.53M |
| EBIT Margin | -217.82% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 60.94M | 19.27M | 30.59M |
| Short-Term Investments | 63.38M | 59.85M | 107.43M |
| Cash & Short-Term Investments | 124.32M | 79.12M | 138.02M |
| Prepaid Expenses | 3.40M | 1.51M | 1.81M |
| Total Current Assets | 127.72M | 80.63M | 139.83M |
| Property, Plant & Equipment | 4.35M | 4.35M | 7.89M |
| Long-Term Investments | 23.77M | 12.07M | 3.01M |
| Other Long-Term Assets | 921.00K | 161.00K | 183.00K |
| Total Assets | 156.76M | 97.22M | 150.91M |
| Accounts Payable | 1.41M | 996.00K | 2.27M |
| Accrued Expenses | 5.94M | 4.41M | 14.38M |
| Current Portion of Leases | 1.46M | 1.02M | 1.85M |
| Current Unearned Revenue | 4.74M | ||
| Other Current Liabilities | 1.33M | 63.00K | 83.00K |
| Total Current Liabilities | 10.14M | 6.49M | 23.33M |
| Long-Term Leases | 1.71M | 1.73M | 2.92M |
| Other Long-Term Liabilities | 249.00K | ||
| Total Liabilities | 11.85M | 8.21M | 26.50M |
| Common Stock | 1.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 4.71M | 4.12M | 2.92M |
| Retained Earnings | -136.76M | -117.56M | -81.10M |
| Comprehensive Income & Other | -97.00K | 97.00K | 253.00K |
| Total Common Equity | -132.14M | -113.34M | -77.93M |
| Shareholders' Equity | 144.91M | 89.00M | 124.41M |
| Total Liabilities & Equity | 156.76M | 97.22M | 150.91M |
| Total Debt | 3.16M | 2.75M | 4.77M |
| Net Cash (Debt) | 144.93M | 88.44M | 136.25M |
| Net Cash Per Share | 10.09 | 6.27 | 10.17 |
| Filing Date Shares Outstanding | 14.65M | 14.34M | 13.40M |
| Total Common Shares Outstanding | 14.65M | 14.34M | 13.40M |
| Working Capital | 117.58M | 74.15M | 116.50M |
| Book Value Per Share | -9.02 | -7.90 | -5.82 |
| Tangible Book Value | -132.14M | -113.34M | -77.93M |
| Tangible Book Value Per Share | -9.02 | -7.90 | -5.82 |
| Machinery | 5.18M | 5.33M | 6.45M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -30.03M | -36.46M | -26.50M |
| Depreciation & Amortization | 2.46M | 2.83M | 2.38M |
| Asset Writedown & Restructuring Costs | 489.00K | ||
| Loss (Gain) From Sale of Investments | -1.13M | -1.77M | -2.91M |
| Stock-Based Compensation | 955.00K | 1.10M | 791.00K |
| Other Operating Activities | -43.00K | 108.00K | -2.00K |
| Change in Accounts Payable | -1.53M | -1.23M | 1.45M |
| Change in Unearned Revenue | -2.44M | -4.74M | -14.94M |
| Change in Other Net Operating Assets | -2.01M | -11.69M | 10.22M |
| Operating Cash Flow | -33.75M | -51.36M | -29.50M |
| Capital Expenditures | -34.00K | -194.00K | -1.27M |
| Sale of Property, Plant & Equipment | 106.00K | 35.00K | |
| Investment in Securities | -5.41M | 40.12M | -58.44M |
| Investing Cash Flow | -5.34M | 39.96M | -59.71M |
| Issuance of Common Stock | 144.00K | 80.00K | 180.00K |
| Repurchase of Common Stock | -3.00K | ||
| Other Financing Activities | -432.00K | -356.00K | |
| Financing Cash Flow | 74.71M | 77.00K | 106.42M |
| Net Cash Flow | 35.62M | -11.32M | 17.21M |
| Free Cash Flow | -33.79M | -51.56M | -30.77M |
| Free Cash Flow Margin | -761.83% | -764.81% | -206.03% |
| Free Cash Flow Per Share | -2.35 | -3.66 | -2.30 |
| Levered Free Cash Flow | -36.92M | ||
| Unlevered Free Cash Flow | -36.90M | ||
| Cash Income Tax Paid | 2.00K | 1.00K | 86.00K |
| Change in Working Capital | -5.97M | -17.66M | -3.27M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.52B | ||
| Enterprise Value | 1.38B | ||
| Debt / Equity Ratio | 0.02 | 0.03 | 0.04 |
| Net Debt / Equity Ratio | -1.00 | -0.99 | -1.09 |
| Net Debt / EBITDA Ratio | 4.41 | 2.29 | 4.34 |
| Net Debt / FCF Ratio | 4.29 | 1.72 | 4.43 |
| Asset Turnover | 0.05 | ||
| Quick Ratio | 12.26 | 12.20 | 5.92 |
| Current Ratio | 12.60 | 12.43 | 5.99 |
| Return on Equity (ROE) | -34.17% | ||
| Return on Assets (ROA) | -20.09% | ||
| Return on Capital Employed (ROCE) | -23.10% | -44.00% | -25.50% |
| Buyback Yield / Dilution | -5.22% |